A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy

We retrospectively analyzed therapeutic strategies and risk factors for overall survival (OS) in disease recurrence following curative nephrectomy for localized renal cell carcinoma (loRCC) using the Korean National Cancer Registry Database. We selected 1295 recurrent loRCC patients who underwent ei...

Full description

Bibliographic Details
Main Authors: Sung Han Kim, Min Gee Choi, Ji Hye Shin, Young-Ae Kim, Jinsoo Chung
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.693831/full
_version_ 1831544719687024640
author Sung Han Kim
Min Gee Choi
Ji Hye Shin
Young-Ae Kim
Jinsoo Chung
author_facet Sung Han Kim
Min Gee Choi
Ji Hye Shin
Young-Ae Kim
Jinsoo Chung
author_sort Sung Han Kim
collection DOAJ
description We retrospectively analyzed therapeutic strategies and risk factors for overall survival (OS) in disease recurrence following curative nephrectomy for localized renal cell carcinoma (loRCC) using the Korean National Cancer Registry Database. We selected 1295 recurrent loRCC patients who underwent either partial or radical nephrectomy from 2007–2013. Patients were excluded for age <19 years, secondary RCC, multiple primary tumors, other SEER stages except for a localized or regional stage, postoperative recurrence within 3-month, and non-nephrectomized cases. Four therapeutic groups were statistically analyzed for OS and risk factors: surgery (OP, 12.0%), other systemic therapy (OST, 59.5%), radiotherapy (RT, 2.8%), and targeted therapy (TT, 25.8%). The overall mortality rate for recurrent loRCC was 32.5%, including 82.4% for RCC-related deaths. The baseline comparison among groups showed statistical differences for the diagnostic age of cancer and the SEER stage (p<0.05). Multivariate analysis of OS showed significance for the TT (hazard ratio [HR]: 6.27), OST (HR: 7.05), and RT (HR: 7.47) groups compared with the OP group, along with significance for the sex, SEER stage, and the time from nephrectomy to treatment for disease recurrence (p<0.05). The median OS curve showed a significantly better OS in the OP group (54.9 months) compared with the TT, OST, and RT groups (41.7, 42.9, and 38.0 months, respectively; p<0.001). In conclusion, the surgery-treated group had the best OS among the different therapeutic strategies for recurrent loRCC after nephrectomy, and the importance of the time from nephrectomy to secondary treatment was a significant prognostic factor.
first_indexed 2024-12-17T01:14:04Z
format Article
id doaj.art-a318a35f17144673bde9b796b8fabe48
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-17T01:14:04Z
publishDate 2021-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-a318a35f17144673bde9b796b8fabe482022-12-21T22:09:03ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.693831693831A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After NephrectomySung Han Kim0Min Gee Choi1Ji Hye Shin2Young-Ae Kim3Jinsoo Chung4Department of Urology, Center for Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, South KoreaNational Cancer Control Institute, National Cancer Center, Goyang, South KoreaNational Cancer Control Institute, National Cancer Center, Goyang, South KoreaNational Cancer Control Institute, National Cancer Center, Goyang, South KoreaDepartment of Urology, Center for Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, South KoreaWe retrospectively analyzed therapeutic strategies and risk factors for overall survival (OS) in disease recurrence following curative nephrectomy for localized renal cell carcinoma (loRCC) using the Korean National Cancer Registry Database. We selected 1295 recurrent loRCC patients who underwent either partial or radical nephrectomy from 2007–2013. Patients were excluded for age <19 years, secondary RCC, multiple primary tumors, other SEER stages except for a localized or regional stage, postoperative recurrence within 3-month, and non-nephrectomized cases. Four therapeutic groups were statistically analyzed for OS and risk factors: surgery (OP, 12.0%), other systemic therapy (OST, 59.5%), radiotherapy (RT, 2.8%), and targeted therapy (TT, 25.8%). The overall mortality rate for recurrent loRCC was 32.5%, including 82.4% for RCC-related deaths. The baseline comparison among groups showed statistical differences for the diagnostic age of cancer and the SEER stage (p<0.05). Multivariate analysis of OS showed significance for the TT (hazard ratio [HR]: 6.27), OST (HR: 7.05), and RT (HR: 7.47) groups compared with the OP group, along with significance for the sex, SEER stage, and the time from nephrectomy to treatment for disease recurrence (p<0.05). The median OS curve showed a significantly better OS in the OP group (54.9 months) compared with the TT, OST, and RT groups (41.7, 42.9, and 38.0 months, respectively; p<0.001). In conclusion, the surgery-treated group had the best OS among the different therapeutic strategies for recurrent loRCC after nephrectomy, and the importance of the time from nephrectomy to secondary treatment was a significant prognostic factor.https://www.frontiersin.org/articles/10.3389/fonc.2021.693831/fullrenal cell carcinomanephrectomytreatmentrecurrenceprognosis
spellingShingle Sung Han Kim
Min Gee Choi
Ji Hye Shin
Young-Ae Kim
Jinsoo Chung
A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy
Frontiers in Oncology
renal cell carcinoma
nephrectomy
treatment
recurrence
prognosis
title A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy
title_full A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy
title_fullStr A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy
title_full_unstemmed A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy
title_short A Real-World, Population-Based Retrospective Analysis of Therapeutic Survival for Recurrent Localized Renal Cell Carcinoma After Nephrectomy
title_sort real world population based retrospective analysis of therapeutic survival for recurrent localized renal cell carcinoma after nephrectomy
topic renal cell carcinoma
nephrectomy
treatment
recurrence
prognosis
url https://www.frontiersin.org/articles/10.3389/fonc.2021.693831/full
work_keys_str_mv AT sunghankim arealworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy
AT mingeechoi arealworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy
AT jihyeshin arealworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy
AT youngaekim arealworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy
AT jinsoochung arealworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy
AT sunghankim realworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy
AT mingeechoi realworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy
AT jihyeshin realworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy
AT youngaekim realworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy
AT jinsoochung realworldpopulationbasedretrospectiveanalysisoftherapeuticsurvivalforrecurrentlocalizedrenalcellcarcinomaafternephrectomy